Shopping Cart 0
Cart Subtotal
USD 0

Pressure Ulcers-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Pressure Ulcers-Pipeline Review, H2 2017

Summary

Global Markets Direct latest Pharmaceutical and Healthcare disease pipeline guide Pressure Ulcers-Pipeline Review, H2 2017, provides an overview of the Pressure Ulcers (Dermatology) pipeline landscape.

Pressure ulcers are an injury that breaks down the skin and underlying tissue. The parts of the body most at risk of developing pressure ulcers are those that are not covered by a large amount of body fat and are in direct contact with a supporting surface (bed or a wheelchair). Causes include continuous pressure, friction and shear. Treatment includes antibiotics and nutrition.

Report Highlights

Global Markets Direct Pharmaceutical and Healthcare latest pipeline guide Pressure Ulcers-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Pressure Ulcers (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pressure Ulcers (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Pressure Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, IND/CTA Filed and Preclinical stages are 3, 1 and 4 respectively.

Pressure Ulcers (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Pressure Ulcers (Dermatology).

The pipeline guide reviews pipeline therapeutics for Pressure Ulcers (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Pressure Ulcers (Dermatology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Pressure Ulcers (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Pressure Ulcers (Dermatology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Pressure Ulcers (Dermatology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Pressure Ulcers (Dermatology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Pressure Ulcers-Overview

Pressure Ulcers-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Pressure Ulcers-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pressure Ulcers-Companies Involved in Therapeutics Development

EyeGene Inc

Izun Pharmaceuticals Corp

MediWound Ltd

NovaLead Pharma Pvt Ltd

RegeneRx Biopharmaceuticals Inc

RMB-Research GmbH

Pressure Ulcers-Drug Profiles

AG-100-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EG-Decorin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EscharEx-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IZN-6D4-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NLP-328-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RGN-137-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Statmicoll-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Pressure Ulcers-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pressure Ulcers-Dormant Projects

Pressure Ulcers-Discontinued Products

Pressure Ulcers-Product Development Milestones

Featured News & Press Releases

Aug 24, 2016: MediWound's EscharEx to be Featured at International Society for Burn Injuries 2016

Dec 04, 2015: RegeneRx Receives Chinese Patent for Key TB4 Peptide Fragment

Jan 09, 2009: RegeneRx Reports Phase II Pressure Ulcer Trial Results

Sep 22, 2008: RegeneRx/Sigma-Tau Completes Patient Enrollment Of Second Phase II Clinical Trial With RGN-137

Aug 20, 2008: RegeneRx Completes Patient Enrollment Of First Phase II Clinical Trial

Nov 02, 2004: RegeneRx Gets Cleared To Initiate Phase II Clinical Trial With T4 For Chronic Pressure Ulcers

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Pressure Ulcers, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Pressure Ulcers, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pressure Ulcers-Pipeline by EyeGene Inc, H2 2017

Pressure Ulcers-Pipeline by Izun Pharmaceuticals Corp, H2 2017

Pressure Ulcers-Pipeline by MediWound Ltd, H2 2017

Pressure Ulcers-Pipeline by NovaLead Pharma Pvt Ltd, H2 2017

Pressure Ulcers-Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2017

Pressure Ulcers-Pipeline by RMB-Research GmbH, H2 2017

Pressure Ulcers-Dormant Projects, H2 2017

Pressure Ulcers-Discontinued Products, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Pressure Ulcers Therapeutic Products under Development, Key Players in Pressure Ulcers Therapeutics, Pressure Ulcers Pipeline Overview, Pressure Ulcers Pipeline, Pressure Ulcers Pipeline Assessment


Companies

EyeGene Inc

Izun Pharmaceuticals Corp

MediWound Ltd

NovaLead Pharma Pvt Ltd

RegeneRx Biopharmaceuticals Inc

RMB-Research GmbH